Pediatric Health Promotion Plan
|
Milestones Newborn (birth to 4 weeks) · Communicates through cries, vision 8-12 inches Infant (4week-12 months) 1 month- · GM: Lifts chin when prone, turns head when supine, largely reflex · FM: hands with tight fist, hands to mouth · Hearing fully developed, grunts, startle reflex, fixates on faces, recognizes parents voice 2 month · GM: Lifts chest & head when prone, turns head when supine. Head bobs if held upright · FM: Tracks past midline (by 4 months), makes eye contacts. Opens and closes hands, hold hands together. · Coos, alerts to voice and sound. Social smile begins (by 6 months). Recognizes parents face. 4 month · GM: Props on wrists when prone. Holds head up, rolls front to back (by 6 months should see). · FM: Tracks to 180’, Grasp, shakes rattle, places items in mouth, reaches for objects. · Teething starts, “converses” in responsive manner to person/parents. Laughs out loud. Looks around-curious (near and distant vision). Smiles spontaneously. Sees color. 6 month · GM: Starts to sit unsupported (by 9 months). Crawls (by 8months). · FM: Reaches with one hand and transfers hand to hand · Babbles, giggles/laughs and listens by nine months, recognizes strangers. 7 months begins to reach out hands in anticipation of being picked up, 8 months should be sitting unassisted, distinguishes different shapes.
9 month · GM: Pulls to stand, cruises, crawls · FM: Pincer grasp, bangs blocks together, holds bottle · Babbles (‘Da-da, Ma-ma’ by now), imitates sounds (understands 1-3 words), responds to name (by 12 months), waves “bye-bye” , reciprocates gestures (by 12 months), uses sound to get attention, stranger anxiety. Object permanence.
Toddler (1 year-3 year) 12 month · GM: Stands alone, first step by some, (walks few steps alone by 18 months). · FM: primitive marks on paper. Finger feeds. · 1 word immature jargon (begins to use 1-2 word jargon through 2cd year), points finger in purposeful direction, pat-a-cake, imitates, follows 1 step commands with gesture
15 month · GM: Walks carrying objects, stoops and recovers, climbs on furniture. · FM: Scribbles, 3-4 cube tower (up to 2 year), turns pages, uses spoon and cup · 3-6 words, says ‘No’ correctly, single step commands w/o gestures 18 month · GM: Walks up steps with hand held, runs, throws ball · FM: Scribbles, 4 cube tower minimum · 10-25 words, points to people and at least three body parts when named, combines language with gestures. Helps in house, removes clothing, imaginative play begins 2 year · GM: Walks down step uses rail. Throws ball overhead. Kicks ball. Jumps, walks on toes, alternates feet going up stairs · FM: Lines cubes up as train, imitates circle and/or line. Turns paper pages in books, 6-8 cubes tower, can turn knobs and open doors. · >50 words 50% intelligible, 2 word phrases, pronouns, can recite parts of familiar book, follows series of independent commands, takes off clothing, parallel play. Washes and dries hands, puts on clothing, imitates adult activities. 3-5 year (preschool) · GM: Runs, jumps, skips, rides tricycle, stand on one foot, constantly in motion. Throws overhead by 5 years. · FM: Can draw intersecting lines (cross, plus sign).
School age (5 years-12 years) · GM: · FM: draws 6 part man (stick figure) beginning at 5 years. Lace shoes.
Adolescent (13 years- 18 years) · Depending on circumstances stage can be 13-20 years of age.
|
Immunization Schedule Direct CDC link with catch up schedule included Birth Hepatitis B (HepB) 1st dose
Screening- ( B.F. Preventive Service link ) · ‘Newborn Screening’ (usually in hospital prior to discharge w/repeat testing in 9 states at 1-2wks) · Hearing birth to 1 month · Vision screening at visits to 3years **All screening just for start them, make sure to check on follow up screenings using the B.F. (Bright Futures) recommendations.
1month-2months Hepatitis B (HepB) 2cd dose
2 month-1st dose Rotavirus (RV): RV1 (2-dose series- If any dose in the series is either RotaTeq or unknown, default to 3-dose series.) Diphtheria, tetanus, acellular pertussis (DTaP <7years) Haemophilus influenzae type b (Hib) Pneumococcal conjugate (PCV13) Inactivated poliovirus (IPV <18 yrs)
4 month-2cd dose Rotavirus (RV): RV1 (2-dose series) Diphtheria, tetanus, acellular pertussis (DTaP <7years) Haemophilus influenzae type b (Hib) Pneumococcal conjugate (PCV13) Inactivated poliovirus (IPV <18 yrs)
Screening-6mth · Risk for Anemia (screen only) · TB screen Q6 months until 2yo then annual.
Starting 6 months Inactivated poliovirus (IPV <18 yrs), Hepatitis B (HepB) 3rd dose (6-18 months) RV5 (3-dose series) Diphtheria, tetanus, acellular pertussis (DTaP <7years) Haemophilus influenzae type b (Hib) (6-15 months, can give 4th dose at 12 months if 3rd dose given at 6 months).
Screening- 9month ( B.F. Preventive Service link ) · Developmental-Behavioral · Finger stick Anemia test · Lead test or screening test
12-18 months Pneumococcal conjugate (PCV13) Measles, mumps, rubella (MMR) Varicella (VAR) Hepatitis A (HepA)-2 dose series
Start of annual Influenza (IIV okay at 6 months) or (LAIV okay at 2 years) 1 or 2 doses
Screening- · Visual screen annually 3-6yo, then · 8yo,10yo,12yo,15yo,18yo · Visual acuity-Preschool age 3-5yo
15 months Diphtheria, tetanus, acellular pertussis (DTaP <7years)
Screening- 18month visit ( B.F. Preventive Service link ) · Risk for Anemia (screen only)
Screening- 2-2.5yr visit ( B.F. Preventive Service link ) · Developmental-Behavioral · Risk for Anemia (screening only from age 2 to age 21). · Finger stick Lead test or screening recommended.
11-12 years Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs) Human papillomavirus (HPV) Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos)
Meningococcal B (high risk group) Pneumococcal polysaccharide (High risk group)
Screening- Adolescence ( B.F. Preventive Service link )
· Adolescent alcohol and substance use · Cervical Dysplasia-The first Pap test approximately 3 years after onset of vaginal intercourse, but no later than age 21. Screening should be done annually with conventional Pap test or liquid-based cytology until age 30. After age 30, Pap tests may be done every 2 to 3 years after 3 normal tests.
16 years Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos) 2cd dose
Screening for STD-
· All sexually active women <25 get chlamydia screening and all sexually active youth get gonorrhea and chlamydia testing annually. High risk-include HIV/Syphillis yearly and change chlamydia to 3-6months testing intervals. See bright futures for discussion on high risk groups. **no child should ever have these so if see please suspect child abuse.
|
Physical Growth & Safety Birth-1 year: · Weight gain 7-8 pounds · Length 19-21 inches · Vital signs- Temp 37.5, P 120-140, R 30-60, BP 80/40 Document · Length-for-age and Weight-for-age · Head circumference-for-age and Weight-for-length 5th to 95th percentile for normal growth and 3rd to 97th for abnormal encounters that specialist use. Link to 5-95th percentile link- Click here
Safety- · Never leave a child alone on a changing table, bed, or sofa. Children can fall as soon as they can roll over. · Use gates on stairways and install window guards on all windows above the first floor as soon as your baby can crawl. · Never leave small objects within your baby's reach. · Never carry hot liquids or food, or cook, while holding your child.
8 to 12 months: · Keep pins and other sharp objects off the floor and out of your baby's reach. · Install safety plugs in wall sockets. · Remove easily overturned lamps and dangling electrical cords. · Place soft adhesive bumpers on the corners of sharp-edged furniture. · Place a gate across stairways to keep the baby from falling down stairs. · Keep medicines and poisons in a locked cabinet. Install child locks on cabinets. · Be sure baby furniture and toys are painted with lead-free paint. Buy age-appropriate toys that are too large to swallow. · Never leave your baby alone in the bath; keep one hand on the child at all times.
12 to 36 months: · Secure doors that lead to stairways, driveways, and storage areas. · Never leave a child alone in a bathtub, wading pool, or other body of water. · Lock medicines away immediately after use. · Lock kerosene, pesticides, and toxic cleaning products in a safe place. · Buy age-appropriate toys that are too large to swallow. · Don't leave your child alone around burning fireplaces, heaters, or other hot appliances. · Provide constant supervision. · Store dangerous tools and gardening equipment in a locked shed or cabinet. · Keep matches and cigarette lighters locked up and out of sight.
Toddler (1-3 year) Document-Length-for-age and Weight-for-age. Head circumference-for-age and Weight-for-length · Stage-Autonomy vs shame · Gains 5-6 pounds a year in this stage. · Head circumference gains 2cm · Round belly · Respirations slow slightly · HR 90-110 · BP 99/64 · Brain develops to 90% adult size · Begins to control urine/bowels with increased sphincter control · 8 new teeth (canines, and molars) · 5th-95th percentile growth charts link- Click here
Safety- · Teach your child the right way to use simple kitchen tools and appliances. · Teach bicycle safety rules and traffic dangers. · Start swimming lessons. Never leave a child unsupervised around a pool or other body of water, even if the child has had swimming lessons.
Preschooler (3-5 year) · Stage- Initiative vs Guilt · P 85 · BP 100/60 · Voiding is frequent (9-10 times daily) · Weight slows down to 4.5 pounds a year · Height gain of 2-3.5 inches · All teeth by now · 5-95th percentile link- Click here
School Age (5-12) · Stage- Industry vs inferiority · Weight 3+ pounds · Height 1-2 inches · Brain growth by age 10 complete · Posture more erect · P 70-80 · BP 112/60 · Secondary sex characteristics develop · Deciduous teeth lost and permanent erupt · 5-95th percentile link- Click here Safety- · Insist that your child wear a helmet when cycling or other appropriate times. Children should wear helmets and wrist and kneepads while skating and skateboarding. · Teach proper use of more complex kitchen appliances. · Be sure your child uses well-fitting, well-maintained sports equipment when practicing or playing a game. · Teach your child basic first aid and what to do in an emergency.
Adolescent (13 years- 18 years) · Stage-Identity vs Roll (13-20 years) · Sexual maturity females 12-18 · Sexual maturity males 14-20 · Onset puberty followed by cessation of body growth · Early-most girls 1-2 inches taller then boys · Boys grow 4-12 inches, gain 15-65 pounds · Girls grow 2-8 inches and gain 15-55 pounds · P 70 · RR 20 · BP 120/70 · Second set of molars by 13 and wisdom teeth or 3rd molars by 18-21 years of age. · 5-95th percentile link- Click here
Tanner stages- Pubic Hair Scale (both males and females) · Stage 1: No hair · Stage 2: Downy hair · Stage 3: Scant terminal hair · Stage 4: Terminal hair that fills the entire triangle overlying the pubic region · Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh Female Breast Development Scale · Stage 1: No glandular breast tissue palpable · Stage 2: Breast bud palpable under areola (1st pubertal sign in females) · Stage 3: Breast tissue palpable outside areola; no areolar development · Stage 4: Areola elevated above contour of the breast, forming “double scoop” appearance · Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion Male External Genitalia Scale · Stage 1: Testicular volume < 4 ml or long axis < 2.5 cm · Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males · Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long) · Stage 4: 15-20 ml (or 4.1-4.5 cm long) · Stage 5: > 20 ml (or > 4.5 cm long) |
Important Links:
Peds mental health, behavioral solutions
https://brightfutures.aap.org/Bright%20Futures%20Documents/BF4_POCKETGUIDE.pdf
https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf
Bright Futures Nutrition and Pocket Guide
Helmet PDF sheets for education
Never enough sleep: a brief history of sleep recommendations for children . Pediatrics, 129(3), 548-556.
COVID-19 Planning Considerations: Guidance for School Re-entry
Guidance on Providing Pediatric Ambulatory Services via Telehealth During COVID-19
CDC: Interim Guidance for Immunization Services During the COVID-19 Pandemic
https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
https://www.apea.com/products/building-blocks-flash-cards-64/
Patient Vaccine Education Handouts (English & Spanish) COVID-19 not available at this time
· VIS—DTaP (Diphtheria, Tetanus, Pertussis) Vaccine FREE
· VIS—Haemophilus Influenzae type b (Hib) Vaccine FREE
· VIS—Hepatitis A Vaccine FREE
· VIS—Hepatitis B Vaccine FREE
· VIS—HPV (Human Papillomavirus) Vaccine FREE
· VIS—Influenza (Flu) Vaccine (Inactivated or Recombinant) FREE
· VIS—Influenza (Live, Intranasal) Vaccine FREE
· VIS—Meningococcal ACWY Vaccine FREE
· VIS—Meningococcal B Vaccine FREE
· VIS—MMR Vaccine (Measles, Mumps, and Rubella) FREE
· VIS—MMRV (Measles, Mumps, Rubella, and Varicella) Vaccine FREE
· VIS—Pneumococcal Conjugate Vaccine (PCV13) FREE
· VIS—Pneumococcal Polysaccharide Vaccine FREE
· VIS—Polio Vaccine FREE
· VIS—Rotavirus Vaccine FREE
· VIS—Td (Tetanus, Diphtheria) Vaccine FREE
· VIS—Tdap (Tetanus, Diphtheria, and Pertussis) Vaccine FREE
· VIS—Varicella (Chickenpox) Vaccine FREE
· VIS—Your Child’s First Vaccines FREE
United States Preventative Services Task Force (USPSTF) Clinical Guide 2014 to Preventative Services
Free Telehealth articles but need to form an account
Clinical Practice Guidelines , courtesy of the American Telemedicine Association, provide a foundation for the deployment of telehealth services. View guidelines.
Center for Connected Health Policy provides resources on telehealth-related laws, regulations and Medicaid programs.
The National Consortium of Telehealth provides assistance, education, and information on telehealth.
CDC. (2018). Talking with Parents about vaccines for infants. Retrieved from https://www.cdc.gov/vaccines/hcp/conversations/talking-with-parents.html
McKee, C., & Bohannon, K. (2016). Exploring the Reason Behind Parental Refusal of Vaccines. The Journal of Pediatric Pharmacology and Therapeutics, 21(2). doi: 10.5863/1551-6776-21.2.104